Moleculin Biotech Inc logo

MBRX

Moleculin Biotech Inc

$1.78

Earnings Summary

Revenue
$0Mn
Net Profits
$-6.87Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Moleculin Biotech Inc’s revenue fell -100% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Moleculin Biotech Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Moleculin Biotech Inc’s net profit fell -54.49% since last year same period to $-6.87Mn in the Q1 2022. On a quarterly growth basis, Moleculin Biotech Inc has generated -142.99% fall in its net profits since last 3-months.

Net Profit Margins:

Moleculin Biotech Inc’s net profit margin fell -Inf% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Moleculin Biotech Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Moleculin Biotech Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.25
EPS Estimate Current Year
-0.25

Highlights

EPS Estimate Current Quarter:

Moleculin Biotech Inc’s earning per share (EPS) estimates for the current quarter stand at -0.25 - a -19.05% fall from last quarter’s estimates.

EPS Estimate Current Year:

Moleculin Biotech Inc’s earning per share (EPS) estimates for the current year stand at -0.25.

Key Ratios

Key ratios of the Moleculin Biotech Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.24
Return on Assets (ROA)
-0.19
Return on Equity (ROE)
-0.28
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Moleculin Biotech Inc’s earning per share (EPS) fell -20% since last year same period to -0.24 in the Q1 2022. This indicates that the Moleculin Biotech Inc has generated -20% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Moleculin Biotech Inc’s return on assets (ROA) stands at -0.19.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Moleculin Biotech Inc’s return on equity (ROE) stands at -0.28.

Dividend Per Share (DPS):

Moleculin Biotech Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-11
-0.21
-0.24
-14.29%

Company Information

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a NextGeneration Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition.

Organisation
Moleculin Biotech Inc
Headquarters
Houston, Texas, United States
Employees
13
Industry
Health Technology